GlassScriptPhysician profile
Alexandra Cleminson
NPI 1891210407
$6,732.20
in general payments reported to CMS, 2019-2025
20 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $482 · 2021: $434 · 2022: $1,067 · 2023: $1,732 · 2024: $1,729 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,744.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,388.57 | 2019-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $1,058.74 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $1,003.25 | 2022-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Allergan, INC. | $551.70 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $539.12 | 2019-2021 | |
| Alcon Vision LLC | $427.78 | 2022-2024 | Rocklatan, Simbrinza, Eysuvis |
| Abbvie INC. | $416.03 | 2022-2025 | Durysta, Lumigan |
| Aerie Pharmaceuticals, INC. | $274.76 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $229.97 | 2021-2025 | Acuvue |
| Johnson & Johnson Surgical Vision, INC. | $211.19 | 2023-2024 | Tecnis Iol, Tecnis Iol, Catalys System |
| Kala Pharmaceuticals, INC. | $158.85 | 2021-2022 | |
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Dompe US, INC. | $97.44 | 2024 | Oxervate |
| Coopervision INC. | $89.93 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $45.02 | 2024 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $33.91 | 2024 | Vevye |
| Glaukos Corporation | $26.14 | 2019 | |
| Thea Pharma INC. | $23.19 | 2023 | Iyuzeh |
| Shire North American Group INC | $19.84 | 2019 | |
| Rxsight INC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Cleminson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.